Travel nurse company asks court to strike down 'unconstitutional' law designed to nullify contracts
In documents filed with the court in Saint John, Canadian Health Labs alleges the Travel Nurses Act represents "unlawful interference" by the legislature of New Brunswick into a "freely negotiated commercial relationship between two commercial entities."
It claims the act was "legislated in bad faith and constitutes an abuse of power by the province."
The act is "improper, unconstitutional and unconscionable and must be struck down in its entirety," Canadian Health Labs argues in the documents, filed in response to Vitalité's statements of defence and counterclaims to the company's three lawsuits over the contracts.
The Ontario-based company has also notified the provincial and federal attorneys general about the "questions of constitutionality raised in this matter," according to the documents.
New Brunswick's attorney general declined to comment Friday through Department of Justice and Public Safety spokesperson Jadesola Emmanuel. She cited the matter being before the courts.
The Office of the Attorney General of Canada has received notice of a constitutional question related to the provincial Travel Nurses Act, confirmed federal Department of Justice spokesperson Ian McLeod. It will "review in order to determine next steps," he said in an emailed statement.
Bill was introduced in March
Health Minister Dr. John Dornan introduced the Act Respecting Travel Nurses in March, after Vitalité cancelled the remaining shifts of travel nurses employed by Canadian Health Labs, even though its contract wasn't set to expire until February 2026.
"The contract that we signed was not a good contract for New Brunswickers, for taxpayers," Dornan said at the time. It was signed in 2022 in the midst of the COVID-19 pandemic and dire staffing shortages, he said. "We were desperate."
Canadian Health Labs charged about $300 an hour per nurse — roughly six times what a local staff nurse earns, Auditor General Paul Martin found in a report last summer. "The contracts with private nursing agencies were not reflective of best practices and did not demonstrate value for money," Martin said.
Two days after the legislation was introduced, Canadian Health Labs launched its first lawsuit against Vitalité, alleging breaches of contract and seeking damages.
Then, before the legislation was adopted, the company filed two more lawsuits over two other contracts, which were also signed in 2022 but had both expired in 2024. Canadian Health Labs alleged, among other things, that Vitalité deployed fewer "human health resource professionals" than stipulated, failed to pay invoices, and terminated a renewal "unilaterally and improperly."
Dornan subsequently appeared before the legislature's standing committee on economic policy to discuss proposed amendments to the bill. Vitalité's lawyers had raised concerns about the expired contracts not being included, Dornan said. So the government decided it would be "prudent, and perhaps safer, to nullify all three contracts," which covered from July 2022 to February 2026 and totalled $98 million, according to the auditor general.
Canadian Health Labs alleges the act "has the effect of allowing Vitalité and the province of New Brunswick to not pay its debts, obtain statutorily protected unjust enrichment, not to be held accountable to the various liabilities Vitalité incurred during its commercial relationship with CHL and attempts to shield Vitalité and the province of New Brunswick from judicial oversight and reprimand for its bad faith conduct."
The "use of legislation to avoid payment of accounts receivable for services rendered is tantamount to theft," it claims.
None of the allegations have been proven in court.
Canadian Health Labs goes on to argue that despite the title of the legislation, the Travel Nurses Act "does not address travel nursing in the province."
Travel nursing contracts between Vitalité and other companies — Canadian Health Labs' competitors — remain in place and "unaffected," it says.
"When the government, acting as a commercial entity, decided it could pay less for the same services, it used its legislative power to deprive CHL of the contracted benefit," according to the documents.
The Court of King's Bench of New Brunswick must be free to hear these matters and determine whether the conduct of Vitalité and/or the province of New Brunswick was unlawful, inequitable or deserving of sanction. - Canadian Health Labs
In addition, "in anticipation of the legislation, Vitalité made a decision not to terminate the contract which would have triggered damages becoming due and owing on the date of termination."
The company argues the government and Vitalité "sought out and induced CHL to enter contractual relationships with Vitalité because of an urgent and desperate need for healthcare providers to keep the hospitals open in New Brunswick," it says.
Vitalité "voluntarily agreed to the terms of the contracts with CHL, with the full knowledge and approval of the province."
"Without CHL providing nurses, patients would have died," it claims.
"The Court of King's Bench of New Brunswick must be free to hear these matters and determine whether the conduct of Vitalité and/or the province of New Brunswick was unlawful, inequitable or deserving of sanction."
If the act is not deemed "entirely unconstitutional," Canadian Health Labs argues the legislation does not prevent it from "bringing an action or arbitration for damages."
In that alternative scenario, the company seeks a declaration that Vitalité is bound by the terms of the contracts with Canadian Health Labs and that arbitration and/or the lawsuits can proceed on their merits.
It also requests that Vitalité's counterclaims be dismissed with costs, and seeks a court order appointing an arbitrator.
Vitalité declined to comment, citing the ongoing court proceedings.
Canadian Health Labs did not respond to a request for comment.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, Bloomberg News reported that AstraZeneca (NASDAQ:AZN) is in discussions with Summit Therapeutics for a licensing agreement concerning an experimental lung cancer drug, with a potential value of up to $15 billion. The proposed deal for the drug, which is known as ivonescimab, could involve an upfront payment of several billion dollars to Summit, in addition to future milestone payments. However, the talks are ongoing and could still fall apart. Summit might even choose to partner with a different company. Neither Summit nor AstraZeneca has officially commented on the report. A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample. Summit Therapeutics secured the rights to ivonescimab through a separate deal worth up to $5 billion with China-based Akeso in December 2022. Under that agreement, Summit gained exclusive rights to develop and commercialize ivonescimab in the US, Canada, Europe, and Japan, while Akeso (OTC:AKESF) retained rights for other regions, including China. The deal included an upfront payment of $500 million to Akeso and potential regulatory and commercial milestones of up to $4.5 billion. Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that discovers, develops, and commercializes patient, physician, caregiver, and societal-friendly medicinal therapies. AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Associated Press
2 hours ago
- Associated Press
Public Advisory - NRA-Amlodipine 5 mg tablets: One lot recalled as some bottles may contain the wrong drug
OTTAWA, ON, July 5, 2025 /CNW/ - Summary Affected products Issue Nora Pharma is recalling one lot of NRA-Amlodipine 5 mg tablets because some bottles may contain the wrong tablets, which have been identified as metoprolol succinate prolonged–release 12.5 mg tablets. NRA-Amlodipine treats high blood pressure and chest pain in adults and children aged 6 to 17. The tablets are white or off-white, octagonal, flat, and scored in the middle with '210' and '5' on one side. The metoprolol succinate prolonged-release 12.5 mg tablets are white, round and scored in the middle. While metoprolol is also used to treat high blood pressure and chest pain, substituting amlodipine (5 mg) with metoprolol (12.5 mg) can lead to serious side effects such as dangerous blood pressure changes (especially dangerously low drops), difficulty breathing, or an abnormally slow heart rate. Patients with other conditions (especially heart failure, asthma, severe peripheral arterial disease, pheochromocytoma, or diabetes) and those taking other medications could experience different side effects with varying levels of severity. Children taking the wrong medication may face a higher risk of serious side effects and potential harm. Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventive actions to stop this issue from reoccurring. The Department will inform the public if any new health risks are identified. What you should do Additional information for health professionals: Également disponible en français SOURCE Health Canada (HC)
Yahoo
9 hours ago
- Yahoo
Justice Department's $15 Billion Crackdown Hits 22 Houston Fraud Cases
(Texas Scorecard) – As part of the U.S. Department of Justice's crackdown on healthcare fraud, more than a dozen individuals from the Houston-area have been charged. Nationwide, 321 individuals have been charged with multiple healthcare-related crimes, including wire fraud, bribery, and other fraudulent schemes. In total, the DOJ uncovered nearly $15 billion in fraudulent claims, and the United States has seized over $245 million in cash, luxury vehicles, and other assets in connection with the takedown. Attorney General Pam Bondi commented on the operation, stating: 'This record-setting health care fraud takedown delivers justice to criminal actors who prey upon our most vulnerable citizens and steal from hardworking American taxpayers. Make no mistake – this administration will not tolerate criminals who line their pockets with taxpayer dollars while endangering the health and safety of our communities.' According to the DOJ, 22 cases were announced Monday in Houston alone. These cases involve a wide array of healthcare fraud schemes, including unlawful distribution of controlled substances—some of which ended up on the black market—along with hospice fraud, kickbacks, and Medicare/Medicaid scams involving unnecessary genetic testing, durable medical equipment, and more. Among the most notable cases are Dera Ogudo (39) and Victoria Martinez (35), both of Richmond, who are accused of running a hospice facility that billed Medicare and Medicaid for end-of-life care while deceiving patients into believing they were receiving standard palliative or in-home services. Ogudo also allegedly paid bribes and kickbacks to Dr. Carlos Munoz, who certified patients for hospice care. The total fraud scheme is estimated at $110 million, with Munoz allegedly receiving over $300,000. Keilan Peterson and Kimberly Martinez of Houston have been charged with their alleged roles in a cash-for-prescriptions scheme operating through Relief Medical Center and GroveCare clinics. According to the indictment, Peterson paid three licensed physicians to give him, Martinez, and other clinic staff access to their electronic prescribing credentials. This allowed them to issue a high volume of prescriptions for controlled substances—including hydrocodone, carisoprodol, and oxycodone—without legitimate medical need. The indictment further alleges that Peterson funneled a portion of these prescriptions to his own business, Next Level Pharmacy, where he obtained the drugs and redistributed them illegally on the black market. In total, Peterson and his associates are accused of issuing more than two million pills, most of which were dispensed without medical justification and outside accepted professional standards. Dr. David Jenson, a podiatrist based in The Woodlands, and his business partner, Nestor Rafael Romero Magallanes, were charged with 14 counts of healthcare fraud for allegedly billing Medicare for expensive bioengineered skin grafts intended for chronic wound treatment. The pair allegedly received over $45 million in reimbursements. Brandy Williams, a Houston pharmacy owner, is accused of paying kickbacks to an unnamed podiatrist in exchange for unnecessary prescription referrals. Her pharmacy reportedly received over $4 million through the scheme. Tyneza Mitchell, a licensed nurse practitioner, allegedly received $2.1 million in Medicaid reimbursements for COVID-era treatments that were never provided. Chad Harper of Pearland is accused of using shell companies to pay bribes and kickbacks to marketers who generated business for his laboratories. The indictment claims Harper was reimbursed around $73 million by Medicare. Rami Abunakira, a Richmond resident involved with a lab in Dallas, is charged with billing Medicare $33.5 million for unnecessary genetic testing. Mahmood Sami Kahn and Suhaib Ahmad Chaudry, two Houston men charged in Illinois, are accused of masterminding a fraudulent COVID-19 testing operation. The pair allegedly manipulated labs in Texas and Illinois to submit false claims through a federal reimbursement program, receiving over $293 million, which they then laundered through multiple bank accounts. Kahn is also charged with wire fraud. U.S. Attorney Nicholas J. Ganjei responded to the sweeping operation: 'Americans rely on Medicare for needed treatments and life-saving care. Those [who] bilk this fund to unlawfully enrich themselves are ultimately stealing from the taxpayer and damaging public confidence in our health system. Today's takedown is a reminder to would-be medical fraudsters that the Department of Justice is always standing guard over the public fisc.'